Skip to main content
Journal ArticleOPEN ACCESS

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study

  • Simões de Carvalho F
  • de Brito Marques F
  • Lopes A
  • et al.
Cureus (2023)
DOI: 10.7759/cureus.33509
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background: New glucose-lowering drugs have shown benefits regarding cardiovascular events, heart failure and kidney-related outcomes in type 2 diabetes (T2D). This study aims to estimate the adequacy of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) prescription to people living with T2D with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF).

Cite

CITATION STYLE

APA

Simões de Carvalho, F., de Brito Marques, F., Lopes, A. E., Lima Ferreira, J., & Príncipe, R. M. (2023). Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study. Cureus. https://doi.org/10.7759/cureus.33509

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free